NCT02852928 European Management Platform for Childhood Interstitial Lung Diseases - chILD-EU Register and Biobank
| NCT ID | NCT02852928 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Matthias Griese |
| Condition | Lung Diseases, Interstitial |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2013-12 |
| Primary Completion | 2028-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2013-12 with a primary completion date of 2028-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Generation of a common European database and biobank Continous assessment and implementation of guidelines and treatment protocols Establishment of a large observational cohort of chILD patients Determination the value of outcomes used in child Assess treatment variations used, deliver data from defined protocols and linked outcomes
Eligibility Criteria
Inclusion Criteria: * all children with suspected or * verified diagnosis of ILD or * masquerading as ILD and * those with rare localized parenchymal lung diseases Exclusion Criteria: * other indication as inclusion criteria
Contact & Investigator
Matthias Griese, Prof.
STUDY CHAIR
Klinikum der Universität München, Dr. von Haunersches Kinderspital
Frequently Asked Questions
Who can join the NCT02852928 clinical trial?
This trial is open to participants of all sexes, studying Lung Diseases, Interstitial. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02852928 currently recruiting?
Yes, NCT02852928 is actively recruiting participants. Contact the research team at Matthias.Griese@med.uni-muenchen.de for enrollment information.
Where is the NCT02852928 trial being conducted?
This trial is being conducted at Hanover, Germany, Ankara, Turkey (Türkiye), Edinburgh, United Kingdom.
Who is sponsoring the NCT02852928 clinical trial?
NCT02852928 is sponsored by Matthias Griese. The principal investigator is Matthias Griese, Prof. at Klinikum der Universität München, Dr. von Haunersches Kinderspital. The trial plans to enroll 1,000 participants.